Dianthus Therapeutics (DNTH) Cash from Investing Activities (2017 - 2025)
Historic Cash from Investing Activities for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to -$201.3 million.
- Dianthus Therapeutics' Cash from Investing Activities rose 2239.67% to -$201.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$183.1 million, marking a year-over-year increase of 3265.18%. This contributed to the annual value of -$286.8 million for FY2024, which is 151614.58% down from last year.
- Dianthus Therapeutics' Cash from Investing Activities amounted to -$201.3 million in Q3 2025, which was up 2239.67% from $26.4 million recorded in Q2 2025.
- In the past 5 years, Dianthus Therapeutics' Cash from Investing Activities ranged from a high of $26.4 million in Q2 2025 and a low of -$259.4 million during Q3 2024
- Its 4-year average for Cash from Investing Activities is -$32.4 million, with a median of -$6.9 million in 2022.
- As far as peak fluctuations go, Dianthus Therapeutics' Cash from Investing Activities skyrocketed by 1704883.72% in 2023, and later crashed by 215435.9% in 2024.
- Over the past 4 years, Dianthus Therapeutics' Cash from Investing Activities (Quarter) stood at -$12.7 million in 2022, then skyrocketed by 34.96% to -$8.2 million in 2023, then plummeted by 180.56% to -$23.1 million in 2024, then crashed by 770.94% to -$201.3 million in 2025.
- Its last three reported values are -$201.3 million in Q3 2025, $26.4 million for Q2 2025, and $14.8 million during Q1 2025.